NVIDIA vs Broadcom Stock: Which Is Best?
If you want to invest in an AI-leading tech company,…
Sell
49
NVCR Quote, Financials, Valuation and Earnings
Last price:
$30.20
Seasonality move
:
-8.57%
Day range:
$30.33 - $31.52
52-week range:
$11.70 - $34.13
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
5.74x
P/B ratio:
9.25x
Volume:
1.7M
Avg. volume:
1.6M
1-year change:
138.62%
Market cap:
$3.3B
Revenue:
$509.3M
EPS (TTM):
-$1.40
Analysts' Opinion
-
Consensus RatingNovoCure has received a consensus rating of Buy. The company's average rating is a Buy based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of --, NovoCure has an estimated upside of 13.53% from its current price of $30.83.
-
Price Target DownsideAccording to analysts, the lowest downside price target is -- representing 100% downside risk from its current price of $30.83.
Fair Value
-
According to the consensus of 0 analysts, NovoCure has 13.53% upside to fair value with a price target of -- per share.
NVCR vs. S&P 500
-
Over the past 5 trading days, NovoCure has underperformed the S&P 500 by -5.85% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
NovoCure does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
NovoCure has grown year-over-year revenues for 4 quarters straight. In the most recent quarter NovoCure reported revenues of $155.1M.
Earnings Growth
-
NovoCure has grown year-over-year earnings for 0 quarters straight. In the most recent quarter NovoCure reported earnings per share of -$0.28.
Enterprise value:
3B
EV / Invested capital:
2.98x
Price / LTM sales:
5.74x
EV / EBIT:
--
EV / Revenue:
5.25x
PEG ratio (5yr expected):
-0.19x
EV / Free cash flow:
-38.75x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$441.5M
Return On Assets:
-12.81%
Net Income Margin (TTM):
-25.93%
Return On Equity:
-40.75%
Return On Invested Capital:
-15.43%
Operating Margin:
-20.69%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $542.6M | $504M | $577.7M | $127.3M | $155.1M | |
| Gross Profit | $427M | $379.4M | $441.5M | $95.2M | $119.7M | |
| Operating Income | -$69.9M | -$224.1M | -$158.9M | -$58.2M | -$32.1M | |
| EBITDA | -$63.7M | -$202.2M | -$103.6M | -$55.4M | -$29.6M | |
| Diluted EPS | -$0.77 | -$1.86 | -$1.40 | -$0.46 | -$0.28 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $383.5M | $1.1B | $1.1B | $1B | $1.1B | |
| Total Assets | $431M | $1.1B | $1.2B | $1.1B | $1.2B | |
| Current Liabilities | $95.3M | $124.5M | $141.1M | $157.2M | $735M | |
| Total Liabilities | $124M | $707.3M | $728.8M | $752.6M | $861.2M | |
| Total Equity | $307M | $413.2M | $445.4M | $393.7M | $360.8M | |
| Total Debt | -- | $561.4M | $564.7M | $568M | $654.5M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $48.9M | -$62.5M | -$37.5M | -$19.3M | $10.4M | |
| Cash From Investing | -$511M | -$42.4M | -$19.5M | $17.3M | $10.2M | |
| Cash From Financing | $15.7M | $17.3M | $89.5M | $1.2M | $100K | |
| Free Cash Flow | $19.7M | -$89.2M | -$78.2M | -$26.6M | -$307K | |
NVCR
Sector
Market Cap
$3.3B
$43.9M
Price % of 52-Week High
90.33%
45.73%
Dividend Yield
0%
0%
Shareholder Yield
-1.25%
-0.74%
1-Year Price Total Return
138.62%
-29.11%
Beta (5-Year)
0.748
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$31.40
200-day SMA
Buy
Level
$18.28
Bollinger Bands (100)
Buy
Level
14.42 - 24.16
Chaikin Money Flow
Sell
Level
-10.7M
20-day SMA
Buy
Level
$27.39
Relative Strength Index (RSI14)
Buy
Level
64.30
ADX Line
Sell
Level
13.78
Williams %R
Neutral
Level
-42.9688
50-day SMA
Buy
Level
$21.00
MACD (12, 26)
Buy
Level
3.36
25-day Aroon Oscillator
Buy
Level
80
On Balance Volume
Neutral
Level
101.5M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (0.8176)
Sell
CA Score
(Annual)
Level (-1.7384)
Buy
Beneish M-Score
(Annual)
Level (-3.1996)
Buy
Momentum Score
Level (8)
Sell
Ohlson Score
Level (1.2252)
Sell
Piotroski F Score
(Annual)
Level (2)
Buy
Quality Ratio Score
Level (6)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
NovoCure Ltd serves in the healthcare sector of the United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.
Stock Forecast FAQ
In the current month, NVCR has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The NVCR average analyst price target in the past 3 months is --.
-
Where Will NovoCure Stock Be In 1 Year?
According to analysts, the consensus estimate is that NovoCure share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About NovoCure?
Analysts are divided on their view about NovoCure share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that NovoCure is a Sell and believe this share price will drop from its current level to --.
-
What Is NovoCure's Price Target?
The price target for NovoCure over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is NVCR A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for NovoCure is a Buy. 0 of 0 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of NVCR?
You can purchase shares of NovoCure via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase NovoCure shares.
-
What Is The NovoCure Share Price Today?
NovoCure was last trading at $30.20 per share. This represents the most recent stock quote for NovoCure. Yesterday, NovoCure closed at $30.83 per share.
-
How To Buy NovoCure Stock Online?
In order to purchase NovoCure stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Will Tyson Foods Stock Bounce Back?
Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
61
QMCO alert for Dec 23
Quantum [QMCO] is down 1.82% over the past day.
Sell
46
NUKK alert for Dec 23
Nukkleus [NUKK] is up 1.43% over the past day.
Sell
1
IIPR alert for Dec 23
Innovative Industrial Properties [IIPR] is down 6.46% over the past day.
